In the past month, the pharmaceutical industry has continued to release the benefits of coronary disease as if it had made an appointment in advance.
First, pharmaceutical giant Merck announced on October 11 that the company's oral drug for coronary disease began to apply for authorization from the US Food and Drug Administration (FDA), and on November 4, it announced that the company's drug was the first to be approved in the United Kingdom, and it was the first specific drug to be approved.
Then, on November 5, Pfizer announced that the company's oral drug for coronary disease plans to submit an application for approval on Thanksgiving this year (November 25, 2021).
Image from: Unsplash
On November 8, another pharmaceutical company released a new coronavirus therapy , Regeneron of the United States announced that its own and Swiss Roche Group's cooperation in the development of the coronavirus antibody cocktail therapy Regen-Cov, within 2-8 months of use, the risk of infection with the crown disease by 81.6%, although not as good as Pfizer's 89%, but higher than Merck's 50%.
During the eight-month trial period, no patients in the Regen-Cov group were hospitalized for COVID-19 infection, while 6 in the control group required hospitalization, one of whom was hospitalized in the first month and the other 5 in the second to eighth months. There were no deaths in either the Regen-Cov group or the control group.
A total of 1683 people participated in the trial, of whom 34% were obese and 37% were 50 years of age or older.
This drug is intended for patients with mild coronary disease over the age of 12 years old and weighing at least 40 kilograms, and cannot be used for patients with severe coronary disease oxygen transfusion.
"Antibody Cocktail Therapy"
The name "antibody cocktail therapy" is easy to cause misunderstanding, not to drink a few sips of cocktail to cure the crown disease, but like a cocktail, mix a variety of drugs. The "antibody cocktail therapy" for the treatment of coronary disease is to mix two antibody drugs to obtain a new drug.
Source: Unsplash
Regeneration yuan added that he has been granted emergency use authorization in the United States, which can be used to treat patients with mild or moderate coronary disease.
In addition, the company is ready to apply to the FDA to expand the use of the coronavirus antibody cocktail therapy, if the application is successful, then this "antibody cocktail therapy" can be used to prevent the crown disease like a vaccine.
For those who have not been vaccinated, or are not physically fit to be vaccinated against covid-19, this cocktail therapy may be another option to prevent COVID-19.
However, this therapy may not be cheap compared to vaccines. Regenerative's chief executive, Len Schleifer, said the company couldn't produce enough antibodies at a "people-friendly" price.